Optimal Use of Ganciclovir and Valganciclovir in Transplanted Patients: How Does It Relate to the Outcome?
Table 2
Doses of Ganciclovir and Valganciclovir in the studied population at different dosing times during patient’s hospitalization.
Doses at different dosing times
Prophylaxis of CMV infection (N = 37)
Treatment of CMV disease (N = 111)
Ganciclovir
Valganciclovir
Ganciclovir
Valganciclovir
First administered dose
2.1 ± 1.3
411.0 ± 117.8
2.8 ± 1.6
512.1 ± 184.5
First optimal dose
1.2 ± 0.9
285.0 ± 183.4
1.8 ± 1.2
400.2 ± 201.7
Appropriateness of administered dose compared to optimal dose
18.1%
38.5%
24.8%
43.2%
Second administered dose
2.4 ± 1.5
456.4 ± 206.2
3.1 ± 0.9
571.9 ± 214.8
Second optimal dose
2.0 ± 1.1
409.0 ± 193.4
2.7 ± 1.8
510.0 ± 321.3
Appropriateness of administered dose compared to optimal dose
29.5%
47.5%
32.4%
41.3%
Third administered dose
2.9 ± 2.1
508.8 ± 198.2
3.4 ± 1.9
684.1 ± 244.5
Third optimal dose
2.3 ± 1.6
412.6 ± 187.5
3.0 ± 2.1
625.0 ± 270.4
Appropriateness of administered dose compared to optimal dose
25.2%
31.6%
29.7%
28.0%
Data presented as mean ± SD of drugs’ doses or % of the patients who received the appropriate dose. Doses are based on mg/day for Valganciclovir and mg/kg/day for Ganciclovir. The administered dose is considered appropriate if it was within the range of 80-120% of the optimal dose. £ In patients receiving antiviral therapy as a part of transplantation regimen, after transplantation surgery.
